DarioHealth (DRIO) Competitors

DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Does the media favor DRIO or LUCD?

In the previous week, Lucid Diagnostics had 1 more articles in the media than DarioHealth. MarketBeat recorded 2 mentions for Lucid Diagnostics and 1 mentions for DarioHealth. DarioHealth's average media sentiment score of 1.87 beat Lucid Diagnostics' score of 1.77 indicating that DarioHealth is being referred to more favorably in the media.

Company	Overall Sentiment
DarioHealth	Very Positive
Lucid Diagnostics	Very Positive

Is DRIO or LUCD more profitable?

DarioHealth has a net margin of -159.80% compared to Lucid Diagnostics' net margin of -1,699.86%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-159.80%	-65.81%	-38.41%
Lucid Diagnostics	-1,699.86%	N/A	-124.27%

Which has more risk & volatility, DRIO or LUCD?

DarioHealth has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of DRIO or LUCD?

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 11.2% of DarioHealth shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has stronger valuation and earnings, DRIO or LUCD?

DarioHealth has higher revenue and earnings than Lucid Diagnostics. DarioHealth is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$27.04M	1.08	-$42.75M	-$0.56	-1.17
Lucid Diagnostics	$4.35M	27.48	-$45.53M	-$1.34	-0.82

Do analysts prefer DRIO or LUCD?

DarioHealth presently has a consensus target price of $2.00, suggesting a potential upside of 204.88%. Lucid Diagnostics has a consensus target price of $3.55, suggesting a potential upside of 221.27%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than DarioHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lucid Diagnostics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Summary

Lucid Diagnostics beats DarioHealth on 9 of the 17 factors compared between the two stocks.